MILRINONE LACTATE INJECTION 1 MG
MILRINONE (MILRINONE LACTATE) : 1 MG · DIN 02244854 · SANDOZ CANADA INCORPORATED
Health Canada status: CANCELLED POST MARKET
What is MILRINONE LACTATE INJECTION?
MILRINONE LACTATE INJECTION 1 MG contains MILRINONE (MILRINONE LACTATE) : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02244854, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 31-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MILRINONE LACTATE INJECTION used for?
Treatment of mild to moderate hypertension and prophylaxis of chronic stable angina pectoris.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02244854 |
|---|---|
| Brand name | MILRINONE LACTATE INJECTION |
| Generic / active ingredient | MILRINONE (MILRINONE LACTATE) : 1 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 1 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | C01CE02 MILRINONE |
| AHFS class | 24:04.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-Jul-2025 |
| Original market date | 2003-06-25 00:00:00 |
How is it administered?
Chronic stable angina and hypertension: Starting dose 20 mg or 30 mg once daily. Maximum daily dose is 90 mg. Swallow whole; do not crush or chew.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15°C and 30°C. Protect from light and moisture.
How is it supplied?
Available in blister packs and bottles of 100 tablets.
Contraindications
Hypersensitivity to nifedipine; pregnancy, breastfeeding; cardiovascular shock; combination with rifampicin; severe aortic stenosis; unstable angina; acute MI.
Warnings and precautions
May cause severe hypotension, exacerbation of angina, or peripheral edema. Use with caution in patients with CHF or severe hepatic impairment. Avoid grapefruit juice.
What can be used instead?
Other Canadian products sharing ATC code C01CE02 MILRINONE. 2 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MILRINONE LACTATE INJECTION USP | 1 MG | SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02521407 |
| MILRINONE LACTATE INJECTION, USP | 1 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02244622 |
| APO-MILRINONE INJECTABLE | 1.0 MG | SOLUTION | APOTEX INC | CANCELLED POST MARKET | DIN 02249820 |
| MILRINONE INJECTION | 1 MG | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02244811 |
| MILRINONE LACTATE INJECTION | 1 MG | SOLUTION | STRIDES PHARMA CANADA INC | APPROVED | DIN 02383519 |
| MILRINONE LACTATE INJECTION | 1 MG | SOLUTION | EUGIA PHARMA INC. | APPROVED | DIN 02538369 |
| MILRINONE LACTATE INJECTION | 1 MG | SOLUTION | STERIMAX INC | APPROVED | DIN 02447908 |
| MILRINONE LACTATE INJECTION | 1 MG | SOLUTION | AURO PHARMA INC | DORMANT | DIN 02470047 |
| MILRINONE LACTATE INJECTION, USP | 1 MG | SOLUTION | JAMP PHARMA CORPORATION | APPROVED | DIN 02539543 |
| PRIMACOR INJECTION 1MG/ML | 1 MG | SOLUTION | SANOFI-SYNTHELABO CANADA INC | CANCELLED POST MARKET | DIN 02006391 |
Who else supplies MILRINONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MILRINONE appears in 8 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.